Biohaven jumps as cancer treatment shows promise in early-stage trial

Biohaven

11/12/2025 16:31

** Shares of drugmaker Biohaven BHVN.N rise 8.5% to $11.50

** Co says its experimental therapy, BHV-1510, in combination with Regeneron Pharmaceuticals' REGN.O Libtayo, showed efficacy and manageable safety across several tumors in an early-stage trial

** Co says patients receiving the treatment every three weeks showed a 72.7% confirmed response

** The combination therapy is being tested among pre-treated patients with advanced cancers - BHVN

** RBC Capital Markets says it "sees these efficacy and safety results as promising"

** Including session moves, stock down 69.2% YTD

 (Reporting by Siddhi Mahatole)

 ((siddhi.mahatole@thomsonreuters.com))